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Abstract 
Background: Intermittent preventive treatment in pregnancy with sulfadoxine/pyrimethamine is contra-indicated 
in HIV-positive pregnant women receiving sulfamethoxazole/trimethoprim prophylaxis. Since mefloquine is being 
considered as a replacement for sulfadoxine/pyrimethamine in this vulnerable population, an investigation on the 
pharmacokinetic interactions of mefloquine, sulfamethoxazole and trimethoprim in pregnant, HIV-infected women 
was performed.
Methods: A double-blinded, placebo-controlled study was conducted with 124 HIV-infected, pregnant women on 
a standard regimen of sulfamethoxazole/trimethoprim prophylaxis. Seventy-two subjects received three doses of 
mefloquine (15 mg/kg) at monthly intervals. Dried blood spots were collected from both placebo and mefloquine 
arms four to 672 h post-administration and on day 7 following a second monthly dose of mefloquine. A novel high-
performance liquid chromatographic method was developed to simultaneously measure mefloquine, sulfameth-
oxazole and trimethoprim from each blood spot. Non-compartmental methods using a naïve-pooled data approach 
were used to determine mefloquine pharmacokinetic parameters.
Results: Sulfamethoxazole/trimethoprim prophylaxis did not noticeably influence mefloquine pharmacokinetics 
relative to reported values. The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) 
were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively. Although trimethoprim steady-state levels were not 
significantly different between arms, sulfamethoxazole levels showed a significant 53 % decrease after mefloquine 
administration relative to the placebo group and returning to pre-dose levels at 28 days.
Conclusions: Although a transient decrease in sulfamethoxazole levels was observed, there was no change in 
hospital admissions due to secondary bacterial infections, implying that mefloquine may have provided antimicrobial 
protection.
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Background
In many parts of Africa, pregnancy is complicated by co-
infection with malaria and human immunodeficiency 
virus (HIV). Maternal malaria was associated with a two-
fold higher HIV-1 viral concentration, and in areas where 
HIV prevalence is greater than 10 % of the population, the 
proportional increase of malaria during pregnancy can 
be from 5.5 to 18.8 % [1]. Some reports show that malaria 
increases the incidence of mother-to-child HIV transmis-
sion as well as contributing to low birth weight and mater-
nal anaemia [1, 2]. In addition, drugs used to treat HIV and 
associated infections may cause serious drug interactions. 
For example, HIV-infected patients receiving co-trimoxa-
zole (sulfamethoxazole/trimethoprim) prophylaxis should 
not take another sulfonamide-containing drug, such as sul-
fadoxine/pyrimethamine (SP), as the risk of sulfonamide-
induced adverse effects is increased. Since physiological 
functions are altered during pregnancy, the pharmacoki-
netics of many anti-malarials are different in pregnant 
women compared to non-pregnant women [3–5].
The only drug currently recommended for malaria 
intermittent preventive treatment (IPTp) during preg-
nancy is SP [6]. The development of resistance to SP, 
as well as safety concerns, has limited the options for 
malaria prevention in pregnant women [7–9]. The Global 
Malaria-in-Pregnancy Consortium aims to identify alter-
natives to SP for IPTp, and has considered mefloquine 
(MQ) as a potential replacement for SP-IPTp. Although 
MQ has been used for treatment of multidrug-resistant 
Plasmodium falciparum infections since the 1960s, there 
have been few MQ pharmacokinetic studies involving 
pregnant women. Pharmacokinetic parameters of many 
drugs are altered in pregnant women due to the differ-
ences in the physiological functions relative to non-preg-
nant women. For example, a controlled study of pregnant 
and non-pregnant women infected with P. falciparum 
showed a significantly lower maximum blood concentra-
tion (Cmax) and a larger volume of distribution (Vd/F) of 
MQ in the pregnant group [10]. In addition, interactions 
with other medications commonly used as prophylaxis 
against opportunistic infections in HIV-infected individ-
uals may influence MQ pharmacokinetics.
The effects of various drugs on co-trimoxazole (CTX) 
levels and the effects of CTX on certain drug levels have 
been assessed in numerous studies. Co-administration 
of lamivudine with CTX resulted in an increased drug 
exposure and decreased clearance of lamivudine [11] 
while disposition of indinavir [12], maraviroc [13] or 
zidovudine [14] was not affected by co-administration 
with CTX. Rifampicin was shown to reduce both tri-
methoprim and sulfamethoxazole concentrations in 
HIV-infected patients [15]. To date, there are no data on 
the interaction between CTX and MQ.
A multicentre, randomized, placebo-controlled, clini-
cal trial was conducted to evaluate the efficacy of MQ for 
IPTp among HIV-infected women receiving CTX (NCT 
00811421: Pan African Clinical Trials Registry PACTR 
2010020001813440) [16]. As part of this larger trial, a 
nested investigation of the pharmacokinetics of MQ and 
its effect on the blood levels of CTX was conducted in 
a sub-sample of HIV-infected pregnant women enrolled 
into the main trial at the site in Kisumu, Kenya.
Methods
Subjects
The double-blinded, placebo-controlled study took place 
at the Siaya District Hospital, situated in an area of west-
ern Kenya with holo-endemic malaria transmission and a 
high prevalence of HIV. The main trial has been described 
in more detail elsewhere [17]. Following clinical exami-
nation, women with a gestational age ≤28  weeks were 
included in the study, whereas IPTp was given only if 
the gestational age was greater than 13 weeks. The MQ 
arm received the first dose of IPTp (15 mg/kg MQ) under 
supervision along with a continued daily dose of CTX 
(800 mg sulfamethoxazole, 160 mg trimethoprim). Each 
MQ tablet contains 250 mg of mefloquine HCl. The num-
ber of MQ tablets administered to a woman was deter-
mined according to the maternal weight at the time of 
first IPTp administration (i.e., a woman weighing 60  kg 
received three-and-a-half MQ tablets). Women in the 
placebo arm received placebo MQ at the same schedule 
as for the MQ arm, as well as CTX. CTX was adminis-
tered daily and a total of three doses of MQ or placebo 
were administered at least 1 month apart. HIV-infected 
pregnant women who met all the enrolment criteria for 
the main trial, and reported having taken CTX on a daily 
basis in the previous 7 days, were invited to participate in 
this nested study. Participants from the main study who 
verbally reported having taken CTX on a daily basis in 
the past week underwent a standard informed consent 
procedure at enrolment into the nested pharmacoki-
netic (PK) study. The institutional review boards of the 
Kenya Medical Research Institute (Nairobi, Kenya), the 
US Centers for Disease Control and Prevention (Atlanta, 
GA, USA) and the Hospital Clinic of Barcelona (Spain) 
approved the study protocol. All women who partici-
pated gave written informed consent.
Sampling frame
A total of 124 HIV-infected pregnant women were 
selected for MQ, sulfamethoxazole (SMX) and trimeth-
oprim (TMP) analysis. After disclosure of the MQ and 
placebo groups, 72 of 124 subjects had received MQ. 
The PK parameters for MQ were determined from this 
group. The subjects were randomly divided into three 
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groups: Group A provided blood samples at two, 14 and 
28 days, Group B provided samples at 4 h, 1 and 7 days, 
and Group C provided samples at 8 h, 3 and 21 days. On 
days 0, 1, 3, 7, 14, 21, and 28, blood samples were col-
lected prior to the next dose of co-trimoxazole in order 
to obtain the minimal steady-state concentrations of 
SMX and TMP. All the subjects provided a sample at day 
0 (pre-dose). Final number of samples collected per time 
point ranged from 13 to 22 with a median of 18. Sixteen 
samples per time point is enough to detect 25 % change 
(α =  0.05, β =  0.02), considering the estimated % coef-
ficient of variation (% CV) for inter-individual MQ blood 
concentration to be 35 % (derived from previous labora-
tory experience performing MQ analyses) (MedCalc Sta-
tistical Software version 13.2.0 (MedCalc Software bvba, 
Ostend, Belgium). At day 7 following a second monthly 
dose of MQ, blood was collected for analysis to observe 
any accumulation.
Blood sample collection
At the appropriate time point, approximately 0.5  ml 
whole blood was collected by venipuncture. Three blood 
spots were prepared on Whatman No 1 filter paper by 
transferring 0.1  ml of whole blood using a positive dis-
placement pipette. The spotted filter papers were air-
dried, individually wrapped, labelled, and transferred to 
plastic bags containing a small amount of silica to pre-
vent moisture accumulation. All dried blood spots were 
stored in a refrigerator (4  °C) until transported to CDC 
via travelling personnel. After delivery, samples were 
stored at −20 °C until analysis.
Analytical procedure
A modification of a high-performance liquid chromato-
graphic (HPLC) method described by Bergqvist et al. was 
used to simultaneously measure TMP, SMX, and MQ in 
dried blood spots [18]. TMP, SMX and MQ analytical 
standards were generously donated by WWARN (World-
wide Antimalarial Resistance Network). A 4.6 × 150 mm, 
5  μ, C18 column (Supelco) coupled to a 2.1  ×  10  mm, 
3.5 μ, RP8 guard column (Symmetryshield) and a mobile 
phase consisting of 30 % acetonitrile and 70 % water con-
taining 20  mM N,N-dimethyloctylamine adjusted to pH 
2.3 with phosphoric acid was used to separate the com-
ponents. The column temperature was set for 30  °C and 
the mobile phase flow rate set for 1  ml/min. The com-
ponents were detected using a diode array detector with 
wavelength set at 280 and 220 nm. Drug extraction from 
dried blood spots was accomplished by combining a solid 
phase technique for sulfonamides [19] with liquid–liq-
uid extraction for MQ [18]. Samples were analysed in 
duplicate. The dried blood spots were cut into four sec-
tions and inserted into a polypropylene tube containing 
100 ml of phenacetin (10 μg/ml in methanol) as an inter-
nal standard for SMX and TMP quantitation and 50  ml 
of the mefloquine derivative WR184806 (29  mg/ml in 
methanol) as an internal standard for MQ quantitation; 
1.5  ml of sodium hydroxide (0.1  M) was added and the 
papers allowed to soak for 10 min. The tubes were rotated 
for 15 min followed by removal of the filter papers. A vol-
ume of 0.25 ml zinc sulfate (1 M) was added and the tubes 
rotated for 15 min followed by centrifugation for 10 min 
at 4000  rpm. The supernatant was added to prepped 
100 mg C8 solid-phase extraction columns and eluted by 
vacuum. The column matrix was washed with 0.5  ml of 
water and the SMX and TMP eluted with 1 ml of acetone 
containing 2  % triethylamine. For the MQ extraction, 
1.5 ml of pH 9 phosphate buffer was added to the pellet 
and sonicated for 10 min; 5 ml of methyl t-butyl ether was 
added and the tubes rotated for 10 min followed by cen-
trifugation for 5 min at 2000 rpm. The organic phase layer 
was transferred to the appropriate tubes containing the 
acetone eluent. Extraction with methyl t-butyl ether was 
repeated and the organic phase combined with the pre-
vious extracts from the appropriate samples. The extract 
was evaporated to dryness with nitrogen, reconstituted 
in mobile phase and injected into the HPLC for analysis. 
The extraction method was not optimized for measuring 
blood levels of the major metabolites, carboxymefloquine 
and N-acetyl sulfadoxine, although these components 
were effectively separated by HPLC. Blood concentrations 
for each component were determined from a standard 
curve consisting of a series of spiked dried blood spots. 
Evaluation of the analysis method for ten standard curve 
runs showed the % coefficient of variation to be 11, 7 and 
26 % for MQ (594 ng/ml), SMX (27.5 mg/ml) and TMP 
(1.8  mg/ml), respectively. The relatively high variation 
for TMP was a result of the low concentrations in blood 
which was approaching detection limits. The % accuracy 
was 4.2, 1.5 and 0.2  % for MQ, SMX and TMP, respec-
tively. Some samples had large unidentified chromato-
graphic peaks that interfered with the analytes, possibly 
resulting from other ingested medications. Therefore, 
blood concentration values for each time point were sub-
jected to the Tukey Outlier Test [20] where values larger 
than the upper quartile plus three times the interquartile 
range were eliminated. Only one outlier, occurring at day 
7 was eliminated from the MQ concentration–time curve. 
No more than two outliers per time point was eliminated 
from the TMP data. The remaining blood concentration 
values were then averaged for each time point and used 
for the pharmacokinetic analysis.
Pharmacokinetic analysis
Pharmacokinetic parameters for MQ were calculated 
based on the use of non-compartmental methods of 
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analysis of naïve-pooled data (NPD) using PK Solutions 
Vers. 2.0 Pharmacokinetic Data Analysis software (Sum-
mit Research Services Montrose, CO, USA). The software 
uses a method based on curve stripping, which resolves 
the concentration–time curve into a series of expo-
nential terms used to calculate the various PK param-
eters. A tri-exponential equation (Concentration  =  A 
× e−α time + D × e−β time + E × e−γ time), previously used 
to describe MQ pharmacokinetics [21], was initially 
applied to create the MQ concentration–time profile 
(Fig.  1) and provide test values for the curve stripping 
process. This equation focuses primarily on the distribu-
tion and elimination phases of the pharmacokinetic curve 
and is appropriate in this circumstance where absorption 
phase kinetics is not truly represented due to the initial 
sample collection at 4  h. Linearity in the terminal por-
tion of a semi-log plot confirmed apparent first-order 
rate processes. Blood samples taken at days 0, 1, 3, 7, 14, 
21, and 28 prior to the next dose of co-trimoxazole repre-
sented the minimal concentration [Css (min)] that occurs 
during steady state. Therefore, the averages of these val-
ues were used to determine the steady-state [Css (min)] 
values for TMP and SMX (Fig.  2). Analysis of variance 
(ANOVA) was performed on the TMP and SMX concen-
tration–time data. The rate at which SMX was increasing 
was determined by using an exponential growth equation 
(y = aebx), where ‘b’ is the rate constant.
Results
Mefloquine pharmacokinetics
Although the population pharmacokinetics (popPK) 
approach can accommodate sparse data and provide 
information on the impact of covariates, it requires the 
use of sophisticated software, which may not be available 
to everyone. A comparison of the popPK approach with 
NPD offers no real advantages when determining PK 
parameters from small sample sizes [22]. Therefore, the 
NPD approach was used. The characteristics of the study 
participants are shown in Table  1. The PK parameters 
for MQ, obtained from the concentration–time profile 
shown in Fig. 1 are compared with parameters from simi-
lar studies (Table 2). A recent study: Rich and population 
pharmacokinetics of mefloquine intermittent preventive 
treatment for malaria in pregnancy in Gabon (Ramharter 
et  al. pers comm) was also conducted as part of a mul-
ticentre trial (NCT 00811421) with parameters included 
in Table 2. Relative to the area-under-the-curves (AUCs) 
from the Gabon trial and Na Bangchang et  al. [10], the 
data suggest HIV-infected pregnant women taking CTX 
may result in enhanced MQ bio-availability. Future stud-
ies using a population-based analysis would be better 
able to determine which parameter is responsible for 
the suggested interaction. The terminal elimination half-
life (t1/2 = 12.0 days) was similar to the mean half-life of 
11.6 days for whole blood MQ in pregnant women given 
Fig. 1 Mefloquine concentration (average ± SE) versus time profile
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125 or 250  mg per week during the third trimester of 
pregnancy [9]. Plasmodium falciparum-infected preg-
nant and non-pregnant Thai women showed more rapid 
whole blood MQ half-lives of 7.2 and 8.1  days, respec-
tively [10]. In comparison, the half-life for whole blood 
MQ in healthy individuals was reported to be 13.8 days 
[21], while plasma half-lives range from 16 to 28  days 
[23–29]. The systemic clearance (CL/f) determined from 
this study was 0.035 l/h/kg. The AUC0→∞ of 431 µg-h/ml 
determined from the study was higher than that reported 
from healthy pregnant women (~300 µg-h/ml) and preg-
nant women infected with P. falciparum (319  µg-h/ml) 
[9, 10]. The observed tmax and Cmax were 4 h and 974 ng/
ml and within the range of values reported from normal 
pregnant women (tmax  =  6, range 3–34  h) and P. falci-
parum pregnant women given 15  mg/kg of mefloquine 
(Cmax  =  1257, range 650–1584  ng/ml) [9, 10]. The tmax 
and Cmax determinations are heavily biased since the first 
sample was collected at 4 h and presents a limitation of 
the study design. The MQ levels at 7  days post second 
dose of 594 ±  80  ng/ml (mean ±  SE, n =  16) was not 
significantly different (p = 0.4) from levels at 7 days post 
first dose (490  ±  99  ng/ml, n  =  11), indicating no sig-
nificant drug accumulation. Although at three half-lives, 
some accumulation can be expected, large inter-individ-
ual variability as well as a small sample size may account 
for the lack of significant drug accumulation.
Sulfamethoxazole/trimethoprim
The presence of MQ did not significantly affect the 
steady-state minimum concentrations [Css (min)] for 
TMP (2.23  µg/ml in placebo arm vs 1.86  µg/ml in MQ 
arm) (Fig.  3). Although the analytical precision (% 
CV  =  26) for TMP measurements may have masked 
any significant differences between arms, these con-
centrations are consistent with those found in healthy 
adults given the same dose (Table  3) [30–32]. In con-
trast, the [Css (min)] for SMX showed as much as a 53 % 
decrease in the MQ arm relative to the placebo arm. An 
ANOVA analysis reveals significant changes in the SMX 
Fig. 2 Comparison of sulfamethoxazole blood levels (average ± SE) 
by treatment group
Table 1 Characteristics of subjects upon enrolment
Median (range)
MQ arm (n = 72) Placebo arm (n = 52)
Age (years) 27 (17–42) 27 (17–42)
Body weight (kg) 57 (40–77) 60 (42–80)
Gestation (weeks) 20 (8–28) 20 (8–28)
Haemoglobin (mg/dL) 10.3 (5.6–15.2) 10.6 (5.7–13.7)
Table 2 Comparison of pharmacokinetic parameters for mefloquine
a Original values converted from moles to grams using the molar mass for mefloquine HCl (414.8 g/mole) for comparison
b Original values divided by mean weight (58.3 kg) of the study subjects for comparison
Reference Matrix Subject description Dose (mg) Cmax  
(ng/ml)
t1/2  
(days)
Vd  
(l/kg)
CL  
(l/h/kg)
AUC0→∞ 
(µg-h/
ml)
Present study Whole blood Pregnant 15 mg/kg 974 12.0 14.4 0.035 431
Ramharter et al. (pers comm) Whole blood Pregnant 15 mg/kg 577a 16.8 30.4b 0.073b 308a
Desjardins et al. [21] Whole blood Males 1000 800 13.8 13.3 0.066 648
Schwartz et al. [23] Plasma African males 1000 954 20.0 14.8 0.020 –
Caucasian males 1000 990 27.5 20.3 0.025
De Souza et al. [26] Plasma Males 1000 21.6 23.2 0.031 587
Na Bangchang et al. [10] Whole blood Pregnant (P. falciparum) 15 mg/kg 1257 7.2 10.8 0.047 319
Whole blood Non-pregnant Females (P. 
falciparum)
15 mg/kg 1617 8.1 10.0 0.043 349
Nosten et al. [9] Whole blood Pregnant 250 mg/week – 11.6 – 0.047 –
125 mg/week
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concentration–time profile in the MQ arm (p < 0.0002) 
while no significant changes (p  >  0.05) were observed 
for SMX in the placebo arm. It was observed that as 
MQ is being eliminated, SMX concentrations gradually 
increase back to original levels (Fig. 2). The average [Css 
(min)] for SMX in the placebo arm (23.8  µg/ml) is less 
than that reported in healthy adults taking the same dose 
(Table  3) [30–32]. Since HIV status has been shown to 
have no effect on the pharmacokinetics of either SMX or 
TMP [33], it is conceivable that low absorption or faster 
metabolism of SMX during pregnancy may occur. In a 
study of the pharmacokinetics of sulfadoxine–pyrimeth-
amine in HIV-infected pregnant women, it was observed 
that pregnancy contributes to lower AUC and shorter 
half-life for sulfadoxine, while HIV status did not show 
any significant influence [34].
Drug interactions can occur as a result of competitive 
or non-competitive inhibition of the Cytochrome p450 
enzyme. The Cytochrome p450 isoform, CYP3A4, has 
been implicated in MQ metabolism since the co-admin-
istration of ketoconazole, a potent inhibitor of CYP3A4 
was shown to significantly increase plasma MQ levels in 
humans [35]. Since SMX and TMP have negligible effects 
on the CYP3A4 isoform [36], it is expected that SMX 
and TMP will have little effect on MQ pharmacokinetics. 
Although, the results did not show any significant changes 
in MQ pharmacokinetics in the presence of steady-
state levels of SMX and TMP, a significant reduction of 
SMX levels upon MQ administration was observed. A 
reduction of SMX levels has also been observed in HIV-
infected individuals administered rifampin and has been 
attributed to enhanced SMX hepatic acetylation [15]. MQ 
or its metabolite, carboxymefloquine may affect SMX 
metabolism similarly. The rapid reduction of SMX levels 
4 h after MQ administration (Fig. 2) may be attributed to 
the presence of either MQ or its metabolite, carboxyme-
floquine. If MQ has a direct effect on SMX metabolism, 
SMX levels would be expected to rise after MQ begins 
its elimination phase at approximately 4  h. Although 
an unexplained elevation of SMX levels is seen at day 
2, the lowest levels occur at day 7 followed by an expo-
nential rise to MQ pre-dose levels at day 28. The rise in 
SMX levels at day 7 corresponds to the beginning of the 
elimination phase (tmax = 9 ± 3 days) for the carboxyme-
floquine metabolite [35]. The rate of SMX increase was 
determined by fitting an exponential growth equation 
(y = aebx) to SMX concentrations from seven to 28 days. 
The growth constant (b) of 0.0015 h−1 is equal to a dou-
bling time of 19 days. The half-life for carboxymefloquine 
of 21 days [35] corresponds to the doubling time of SMX 
of 19  days, suggesting that the presence of the carbox-
ymefloquine metabolite may influence SMX metabolism. 
A recent study has shown that the major metabolite of 
MQ, carboxymefloquine induces the expression of drug 
metabolizing enzymes and transporters by activating the 
pregnane X receptor [37].
Limitations of this study include the lack of sufficient 
blood samples collected during the MQ absorption phase 
to obtain accurate tmax, Cmax, as well as the absorption 
rate constant (ka). Obtaining multiple blood samples in a 
short period of time required for absorption phase kinet-
ics is difficult under the conditions encountered in devel-
oping countries. Drug metabolites were not quantified 
using the described analytical technique, therefore any 
associations with metabolite levels could not be made 
directly. Although no significant differences were seen for 
TMP between the MQ and placebo arm, low levels and 
high variability may have masked any changes. Over 95 % 
of the subjects in the study were taking an antiretroviral 
medication (mostly zidovudine, lamivudine, and nevirap-
ine) concomitant with MQ and CTX. Possible interac-
tions with these antiretrovirals cannot be ruled out.
Fig. 3 Comparison of trimethoprim blood levels (average ± SE) by 
treatment group
Table 3 Reported minimum steady-state values Css (min) 
for  sulfamethoxazole (SMX) and  trimethoprim (TMP) 
in previous studies
a Plasma concentration converted to whole blood equivalents using blood/
plasma ratio [39]
SMX (mg ml−1) TMP (mg ml−1) References
23.8 2.2 Present study
45.5a 2.2a Kremers et al. [32]
35.6 1.5 Nowak et al. [31]
43.4 2.98 Kaplan et al. [30]
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Conclusions
This is the first study assessing the pharmacokinetic 
inter-relationship of MQ and CTX. In this study, prophy-
lactic levels of CTX did not significantly alter MQ phar-
macokinetics in HIV-infected pregnant women relative 
to reported parameters in pregnant women not receiving 
CTX. While exposure to MQ did not affect TMP levels, 
there is concern that the transient decline in SMX levels 
would result in an increase in hospital admissions from 
secondary bacterial infections. However, this was not the 
case. Results from the multi-site clinical trial from which 
this study is derived do not support this assertion [17]. 
This implies that that the antimicrobial properties of MQ 
may have provided some protection against microbial 
infections [38].
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